#238 In COPD puffers, does three-of-kind beat a pair?
CLINICAL QUESTION
In Chronic Obstructive Pulmonary Disease (COPD) patients on Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting Beta-Agonist (LABA) dual therapy, does adding inhaled corticosteroids (ICS) improve outcomes?
BOTTOM LINE
In COPD patients with ≥1 exacerbation per year, triple therapy reduces the risk of having ≥1 exacerbations/year compared to LAMA/LABA dual therapy (one less patient for every 36) but increases the risk of pneumonia (one more patient for every 34) and costs. It is possible that higher blood eosinophil counts (>150-300 cells/µL) may help target adding ICS.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- 2019 systematic review: 4 randomized, controlled trials (RCTs) comparing triple versus LAMA/LABA dual therapy in 9310 patients for 24-52 weeks, usually in patients with ≥1 exacerbation/year.1
- Less exacerbations with triple therapy, Rate Ratio 0.71 (0.60-0.84).
- Clinically important quality of life improvement (2 RCTs):
- 50% versus 44% (dual therapy), number needed to treat (NNT)=17.
- Serious adverse events or discontinuation due to adverse events similar.
- Patients with ≥1 pneumonia: 6.4% versus 3.9% (dual therapy), statistically significant.
- Largest RCT of above systematic review, 6221 patients on umeclidinium/vilanterol/fluticasone (triple therapy) or umeclidinium/vilanterol (LAMA/LABA dual therapy). [Vilanterol/fluticasone arm not reported here].2 At 1 year:
- Exacerbation rate and quality of life similar to above systematic review.
- Patients with ≥1 exacerbation (data from sponsor, statistics by TFP authors):
- Triple 47% versus dual therapy 50% (statistically significant, NNT=36).
- Patients with ≥1 pneumonia: triple 7.6% versus dual therapy 4.7% (statistically significant, number needed to harm=34).
- Other systematic reviews found similar.3,4
- Exacerbations in RCTs defined as moderate (needing oral steroids and/or antibiotics) or severe (leading to hospitalization or death).
- Subgroup analyses suggest individuals with higher blood eosinophil counts (>150-300 cells/µL) benefit more from triple therapy, but amount of benefit is not quantifiable.4,5
- Targeting treatment by eosinophils has not specifically been tested in large RCTs.
- Newest guideline suggests adding ICS in patients who develop further exacerbations on LABA/LAMA therapy (and have blood eosinophil counts ≥100cells/µL).6
- When withdrawing ICS from triple, there is a small (6-8% relative), but not statistically different, increase in exacerbations.7,8
- Average annual cost: ~$1100 for dual versus ~$1700 for triple therapy.9
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
